1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Abcam plc

Abcam plc

ABCZF
Abcam plcUS flagOther OTC
22.25
USD
+0.15
- -
5.12BMarket Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2021 Y
2022 Y
Revenue per Share
0.46
0.53
0.62
0.64
0.72
0.85
1.07
1.14
1.27
1.25
- -
1.39
1.58
Basic EPS, GAAP
0.13
0.14
0.17
0.17
0.19
0.19
0.21
0.3
0.22
0.06
- -
0.02
-0.04
Free Cash Flow per Basic Share
0.14
0.12
0.16
0.17
0.16
0.16
0.23
0.13
0.15
0.13
- -
0.01
-0.06
Dividend per Share
0.04
0.05
0.06
0.07
0.08
0.08
0.09
0.11
0.12
0.12
- -
- -
- -
Book Value per Share
0.3
0.38
0.46
0.55
0.66
0.82
0.94
1.15
1.26
1.23
- -
1.28
1.32
Tangible Book Value per Share
0.39
0.17
0.28
0.39
0.42
0.39
0.58
0.64
0.77
0.75
- -
0.25
0.44
Basic Weighted Avg Shares
180
185
198
199
200
201
203
204
205
208
- -
227
229
Sales/Revenue/Turnover
83
98
122
128
144
172
217
233
260
260
298
315
362
Operating Margin (%)
38.08
34.99
35.06
33.85
31.75
26.98
25.38
32.33
21.59
4.04
11.66
2.25
-2.79
Depreciation Expense
2
3
6
7
8
11
15
13
15
30
9
41
53
Net Income, GAAP
24
25
33
34
37
37
42
62
45
12
15
4
-8
Effective Tax Rate (%)
25.87
26.7
23.86
21.83
18.9
17.58
18.3
9.99
20.21
- -
36.52
6.38
- -
Profit Margin (%)
28.59
25.97
26.72
26.61
25.96
21.8
19.53
26.67
17.31
4.81
4.9
1.4
-2.35
Working Capital
64
34
53
74
79
86
111
111
126
119
- -
24
54
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
120
- -
101
96
Total Equity
74
148
170
181
214
261
307
352
383
501
- -
656
727
Return on Invested Capital (%)
35.35
21.92
20.06
18.91
18.37
15.84
15.71
20.41
12.1
- -
5.98
1.49
- -
Return on Capital (%)
52.13
40.86
40.56
33.83
30.92
25.29
25.44
29.24
18.33
- -
6.81
2.31
- -
Return on Common Equity (%)
52.13
40.81
40.56
33.83
30.92
25.29
23.87
29.24
18.23
4.87
11.48
3.03
-2.88

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
10.79%
Free Cash Flow
-62.21%
-124.97%
-506.45%
Net Income, GAAP
-37.2%
-89.22%
-293.18%
Sales/Revenue/Turnover
11.7%
9.32%
14.68%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
315
2022
- -
- -
- -
- -
362
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
0.02
2022
- -
- -
- -
- -
-0.04
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

MCPAPIChat
CEO
Markus Lusser
Full Time Employees
1,760
Sector
Healthcare
Industry
Biotechnology
Address
Discovery Drive Cambridge United Kingdom CB2 0AX
IPO Date
Apr 11, 2011
CIK
0001492074
Website
abcam.com
Similar Companies
Innovent Biologics, Inc. (1801.HK)
GI Innovation, Inc. (358570.KQ)
NKGen Biotech, Inc. Common Stock (NKGN)
Fractyl Health, Inc. Common Stock (GUTS)
EvoNext Holdings S.A. (EVE.SW)
LeonaBio, Inc. (LONA)
Business
Abcam plc is a global life sciences company specializing in the development, manufacture, and distribution of research-grade antibodies, proteins, and related reagents used in biomedical research, diagnostics, and drug discovery. Its core product offerings include primary and secondary antibodies; recombinant proteins; assay kits; custom antibody production services; and research tools for applications such as immunohistochemistry, western blotting, flow cytometry, and ELISA. Abcam serves academic, pharmaceutical, biotechnology, and diagnostic customers worldwide, with operations spanning North America, Europe, and Asia. Founded in 1998 and headquartered in Cambridge, United Kingdom, Abcam has established itself as a key provider in the research reagents industry. In the last 1-2 years, Abcam plc has focused on expanding its product portfolio and geographic reach through strategic acquisitions and partnerships. Recent initiatives include launching novel antibody and protein products targeting emerging biomedical research needs and enhancing its custom service offerings to accelerate drug development workflows. The company has also pursued digital transformation to streamline customer engagement and scientific support. These moves support Abcam's strategic emphasis on innovation-driven growth and broadening its presence in key research markets globally. Abcam remains publicly traded and continues to invest in R&D and global infrastructure to maintain market leadership in life science research reagents.